Encouraging results for PD-1 inhibition in gastric cancer
Mené sur 39 patients atteints d'un adécarcinome métastatique ou récidivant de l'estomac ou de la jonction œso-gastrique surexprimant PD-L1, cet essai international de phase Ib évalue la toxicité et l'acitivité antitumorale du pembrolizumab
The prognosis for advanced gastric cancer is poor: less than 10–15% of patients with metastases live for more than 2 years. Trastuzumab and ramucirumab have resulted in modest improvements in overall survival for patients with HER2-positive gastric cancer and in the second-line setting, respectively. However, these drugs are notable for their success in a field in which there have been many failures. Within this challenging therapeutic context, the results of the KEYNOTE-012 study by Kei Muro and colleagues are promising.
The Lancet Oncology , commentaire, 2015